Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Plus: Why Krispy Kreme left McDonald's, Boeing's latest woes, the potential Shell-BP merger, Bumble's stumble, Nvidia's cloud ...

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.

Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand Mounjaro in the last three months of the year, although, they still ...

Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.